Results 301 to 310 of about 296,757 (381)

Fenotypic expressions and clinical manifestations of arrhythmogenic cardiomyopathy. [PDF]

Eur Heart J Suppl
Setti M, De Luca A, Paldino A, Del Mestre E, Bassetto G, Perotto M, Radesich C, Merro E, Rossi M, Girotto G, Gigli M, Dal Ferro M, Benfari G, Ribichini FL, Merlo M, Sinagra G.   +15 more
europepmc   +1 more source

Extended Use of Intra-aortic Balloon Pumping in Peripartum Cardiomyopathy

, 1976
Charles O. Brantigan, John B. Grow, Fred W. Schoonmaker   +2 more
openalex   +2 more sources

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Advancing clinical management of left ventricular thrombosis: prevention, detection and treatment modalities in the modern era. [PDF]

Heart
Zhang Q, Zheng H, Zhang Z, Xu Y, Zhang W.   +4 more
europepmc   +1 more source

Left atrial function in uraemic patients: Four‐dimensional automatic left atrial quantitative technology study

ESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley   +1 more source

Exploring the c.406 C > T variant in TNNI3 gene: pathogenic insights into restrictive cardiomyopathy. [PDF]

BMC Med Genomics
Masoumi T, Hesami H, Maleki M, Kalayinia S.   +3 more
europepmc   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

The 'Padua classification' of cardiomyopathies into three groups: hypertrophic/restrictive, dilated/hypokinetic, and scarring/arrhythmogenic. [PDF]

Eur Heart J Suppl
Corrado D, Graziano F, Bauce B, Bueno Marinas M, Calore C, Celeghin R, Cipriani A, De Gaspari M, De Lazzari M, Migliore F, Perazzolo Marra M, Pilichou K, Rigato I, Rizzo S, Angelini A, Zorzi A, Thiene G, Basso C.   +17 more
europepmc   +1 more source

Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology.

British heart journal, 1994
G. Thiene, A. Nava, F. Fontaliran, Carina Blomström-Lundqvist, Saroja Bharati, F. Camerini, Piazza Ospedale, D. Corrado, Francesca Lobo, W. McKenna, Cranmer Terrace, Ryoso Okada, Peter Richardson   +12 more
semanticscholar   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source